查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1612623

血流感染檢測市場：依產品類型、技術和最終用途分類－2025-2030 年全球預測

Bloodstream Infection Testing Market by Product (Instruments, Reagents & Consumables), Sample Type (Blood Culture, Whole Blood), Technology, End-use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

血流感染檢測市場2023年估值為11.2億美元，預計到2024年將達到12億美元，複合年成長率為7.64%，到2030年將達到18.8億美元。

血流感染 (BSI) 檢測在診斷進入血液的感染疾病發揮重要作用，這種感染可能導致敗血症等嚴重。此類檢測的範圍包括多種方法，包括傳統的血液培養技術和旨在快速識別病原體的先進分子檢測技術。這些測試對於及時診斷至關重要，這對於有效的患者管理和治療至關重要。典型應用包括醫院、診斷實驗室和專業臨床環境，用於檢測細菌、真菌和病毒病原體。最終用途領域廣泛，包括醫療機構、研究機構和專注於開發新型治療策略的製藥公司。

主要市場統計
基準年[2023] 11.2億美元
預計年份 [2024] 12億美元
預測年份 [2030] 18.8億美元
複合年成長率（%） 7.64%

血流感染檢測市場的成長是由醫院感染數量增加、人口老化加劇以及診斷技術進步等因素所推動的。此外，對快速結果的需求不斷成長，刺激了自動化就地檢驗設備的採用。特別是在醫療保健服務和基礎設施不斷擴大的新興市場，快速、經濟高效且高度敏感的診斷工具的開發和商業化存在潛在的商機。公司應專注於與生物技術公司合作開發和分銷套件，以最大限度地提高市場滲透率。

然而，他們面臨先進測試工具成本高昂、部分地區報銷場景有限等挑戰。此外，某些診斷測試的複雜性可能會阻礙其在資源匱乏的環境中的廣泛使用。新技術的發展可以集中在提高分子診斷工具的準確性和速度，以及開發價格實惠的攜帶式檢測套組。優先研究奈米技術和微流體有可能產生創新的診斷解決方案並促進廣泛使用。市場競爭激烈，技術日新月異，需要不斷研究與適應。企業應尋求協同效應合作並投資於前沿研究，以保持競爭力並有效解決未滿足的需求。

市場動態：揭示快速發展的血流感染檢測市場的關鍵市場洞察

供需的動態交互作用正在改變血流感染檢測市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球血流感染疾病呈上升趨勢
    • 傾向於利用基於血液的診斷策略
    • 政府努力提高人們對血液相關疾病的認知並改善血液安全
  • 市場限制因素
    • 報銷政策複雜且保險範圍不足
  • 市場機會
    • 開發新血液檢測、基於血液的抗生素檢測和次世代定序儀的研究活動
    • 採用人工智慧、機器學習技術和新生物標記進行血流感染檢測
  • 市場挑戰
    • 血流感染檢測的技術和臨床局限性以及污染的可能性

波特五力：駕馭血流感染檢測市場的策略工具

波特的五力框架是了解血流感染檢測市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解血流感染檢測市場的外部影響

外部宏觀環境因素在塑造血流感染檢測市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解血流感染檢測市場的競爭狀況

對血流感染測試市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣血流感染檢測市場供應商績效評估

FPNV定位矩陣是評估血流感染檢測市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，繪製血流感染檢測市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對血流感染檢測市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地的血流感染疾病呈上升趨勢
      • 使用基於血液的診斷策略的趨勢
      • 政府旨在提高人們對血液相關疾病的認知並改善血液安全的舉措
    • 抑制因素
      • 報銷政策複雜且保險範圍不足
    • 機會
      • 旨在開發新的血液檢測、基於血液的抗菌檢測和次世代定序的研究活動
      • 採用人工智慧、機器學習技術和新生物標記進行血流感染檢測
    • 任務
      • 血流感染檢測的技術和臨床局限性以及污染的可能性
  • 市場區隔分析
    • 產品：探索血流感染檢測設備以獲得快速可靠的檢測結果
    • 最終用途：診斷中心的多功能用途，以實現高效測試
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章血流感染檢測市場：依產品

  • 裝置
  • 試劑/耗材

第7章依樣本類型分類的血流感染檢測市場

  • 血液培養
  • 全血

第8章血流感染檢測市場：依技術分類

  • 原位雜合技術
  • 質譜分析
  • PCR

第9章血流感染檢測市場：依最終用途分類

  • 學術研究所
  • 診斷中心
  • 醫院

第10章美洲血流感染檢測市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太血流感染檢測市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲的血流感染檢測市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 將血液檢測和人工智慧結合，實現敗血症管理中的高階診斷、早期檢測和風險評估
    • 戰略夥伴關係加強了波蘭對血流感染疾病和敗血症的診斷
    • Oxford Nanopore 與 Day Zero Diagnostics 之間的創新合作，用於快速血流感染疾病診斷
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Accelerate Diagnostics, Inc.
  • Advacare Pharma
  • Bactiguard AB
  • Becton, Dickinson and Company
  • BioMerieux
  • Bruker Corporation
  • Cardinal Health
  • Cepheid
  • CorMedix Inc.
  • Diasorin SpA
  • F. Hoffmann-La Roche Ltd
  • Fresenius Medical Care AG & Co. KGaA
  • HiMedia Laboratories Pvt. Ltd
  • ITL Health Group
  • Johnson & Johnson Services, Inc
  • Kurin Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Holdings A/S
  • Pfizer Inc.
  • Pro-Lab Diagnostics
  • Sanofi SA
  • Sepsis Alliance
  • Thermo Fisher Scientific Inc.
Product Code: MRR-4D00F1312BD4

The Bloodstream Infection Testing Market was valued at USD 1.12 billion in 2023, expected to reach USD 1.20 billion in 2024, and is projected to grow at a CAGR of 7.64%, to USD 1.88 billion by 2030.

Bloodstream infection (BSI) testing plays a vital role in diagnosing infections that enter the bloodstream, potentially leading to serious conditions like sepsis. The scope of such testing encompasses various methods, including traditional blood culture techniques and advanced molecular testing technologies, designed to identify pathogens rapidly. These tests are essential for timely diagnosis, which is crucial for effective patient management and treatment. The primary applications extend across hospitals, diagnostic laboratories, and specialized clinical settings, where they are used to detect bacterial, fungal, or viral pathogens. End-use sectors range widely, covering healthcare facilities, research institutions, and pharmaceutical companies that focus on developing novel therapeutic strategies.

KEY MARKET STATISTICS
Base Year [2023] USD 1.12 billion
Estimated Year [2024] USD 1.20 billion
Forecast Year [2030] USD 1.88 billion
CAGR (%) 7.64%

Market growth in bloodstream infection testing is driven by factors such as the increasing prevalence of hospital-acquired infections, the growing aging population, and advancements in diagnostic technologies. Furthermore, the rising demand for speedy results has fueled the adoption of automated and point-of-care testing devices. Potential opportunities lie in the development and commercialization of rapid, cost-effective, and highly sensitive diagnostic tools, especially in emerging markets where healthcare access and infrastructure are expanding. Companies should focus on partnerships and collaborations with biotech firms for kit development and distribution to maximize market penetration.

However, the market faces challenges such as high costs of advanced testing tools and limited reimbursement scenarios in some regions. Additionally, the complexity of certain diagnostic tests can hinder widespread adoption in lower-resource settings. Emerging innovations could focus on enhancing the accuracy and speed of molecular diagnostic tools and developing affordable, portable testing kits. Prioritizing research in nanotechnology and microfluidics could yield transformative diagnostic solutions, facilitating broad accessibility. The market is characterized by high competition with rapid technological turnover, necessitating continuous research and adaptation. Enterprises should look to synergistic collaborations and invest in cutting-edge research to maintain a competitive edge and address unmet clinical needs effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bloodstream Infection Testing Market

The Bloodstream Infection Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising number of bloodstream infections across the world
    • Inclination towards utilization of blood-based diagnostics strategies
    • Government initiatives to raise awareness about blood-related diseases and improve blood safety
  • Market Restraints
    • Complex reimbursement policies and inadequate insurance coverage
  • Market Opportunities
    • Research activities to develop novel blood tests, blood-based antimicrobial tests, and next-generation sequencing
    • Adoption of AI, ML technologies, and new biomarkers for bloodstream infection testing
  • Market Challenges
    • Technical and clinical limitations of bloodstream infection testing and chances of contamination

Porter's Five Forces: A Strategic Tool for Navigating the Bloodstream Infection Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bloodstream Infection Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bloodstream Infection Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bloodstream Infection Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bloodstream Infection Testing Market

A detailed market share analysis in the Bloodstream Infection Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bloodstream Infection Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bloodstream Infection Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bloodstream Infection Testing Market

A strategic analysis of the Bloodstream Infection Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bloodstream Infection Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Accelerate Diagnostics, Inc., Advacare Pharma, Bactiguard AB, Becton, Dickinson and Company, BioMerieux, Bruker Corporation, Cardinal Health, Cepheid, CorMedix Inc., Diasorin S.p.A., F. Hoffmann-La Roche Ltd, Fresenius Medical Care AG & Co. KGaA, HiMedia Laboratories Pvt. Ltd, ITL Health Group, Johnson & Johnson Services, Inc, Kurin Inc., Merck & Co., Inc., Novartis AG, Novo Holdings A/S, Pfizer Inc., Pro-Lab Diagnostics, Sanofi S.A., Sepsis Alliance, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Bloodstream Infection Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Instruments and Reagents & Consumables.
  • Based on Sample Type, market is studied across Blood Culture and Whole Blood.
  • Based on Technology, market is studied across In Situ Hybridization, Mass Spectroscopy, and PCR.
  • Based on End-use, market is studied across Academic & Research Institutes, Diagnostic Centers, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising number of bloodstream infections across the world
      • 5.1.1.2. Inclination towards utilization of blood-based diagnostics strategies
      • 5.1.1.3. Government initiatives to raise awareness about blood-related diseases and improve blood safety
    • 5.1.2. Restraints
      • 5.1.2.1. Complex reimbursement policies and inadequate insurance coverage
    • 5.1.3. Opportunities
      • 5.1.3.1. Research activities to develop novel blood tests, blood-based antimicrobial tests, and next-generation sequencing
      • 5.1.3.2. Adoption of AI, ML technologies, and new biomarkers for bloodstream infection testing
    • 5.1.4. Challenges
      • 5.1.4.1. Technical and clinical limitations of bloodstream infection testing and chances of contamination
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Exploring bloodstream infection testing instruments for rapid and reliable test results
    • 5.2.2. End-use: Diverse scope of applications in diagnostic centers for efficient testing
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bloodstream Infection Testing Market, by Product

  • 6.1. Introduction
  • 6.2. Instruments
  • 6.3. Reagents & Consumables

7. Bloodstream Infection Testing Market, by Sample Type

  • 7.1. Introduction
  • 7.2. Blood Culture
  • 7.3. Whole Blood

8. Bloodstream Infection Testing Market, by Technology

  • 8.1. Introduction
  • 8.2. In Situ Hybridization
  • 8.3. Mass Spectroscopy
  • 8.4. PCR

9. Bloodstream Infection Testing Market, by End-use

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. Diagnostic Centers
  • 9.4. Hospitals

10. Americas Bloodstream Infection Testing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Bloodstream Infection Testing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Bloodstream Infection Testing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Advanced Diagnostics in Sepsis Management, Integrating Blood Testing and AI for Early Detection and Risk Assessment
    • 13.3.2. Strategic Partnership Enhances Bloodstream Infection and Sepsis Diagnostics in Poland
    • 13.3.3. Innovative Collaboration for Rapid Bloodstream Infection Diagnostics, Oxford Nanopore and Day Zero Diagnostics Join Forces
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Accelerate Diagnostics, Inc.
  • 3. Advacare Pharma
  • 4. Bactiguard AB
  • 5. Becton, Dickinson and Company
  • 6. BioMerieux
  • 7. Bruker Corporation
  • 8. Cardinal Health
  • 9. Cepheid
  • 10. CorMedix Inc.
  • 11. Diasorin S.p.A.
  • 12. F. Hoffmann-La Roche Ltd
  • 13. Fresenius Medical Care AG & Co. KGaA
  • 14. HiMedia Laboratories Pvt. Ltd
  • 15. ITL Health Group
  • 16. Johnson & Johnson Services, Inc
  • 17. Kurin Inc.
  • 18. Merck & Co., Inc.
  • 19. Novartis AG
  • 20. Novo Holdings A/S
  • 21. Pfizer Inc.
  • 22. Pro-Lab Diagnostics
  • 23. Sanofi S.A.
  • 24. Sepsis Alliance
  • 25. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. BLOODSTREAM INFECTION TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. BLOODSTREAM INFECTION TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. BLOODSTREAM INFECTION TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. BLOODSTREAM INFECTION TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BLOODSTREAM INFECTION TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BLOODSTREAM INFECTION TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BLOOD CULTURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROSCOPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PCR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 189. BLOODSTREAM INFECTION TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. BLOODSTREAM INFECTION TESTING MARKET, FPNV POSITIONING MATRIX, 2023